Chong Kun Dang Pharmaceutical Corp.

Korean pharmaceutical companies, including Chong Kun Dang, Yuhan Corp., Daewoong Pharmaceutical, Hanmi Group, and GC Biopharma, outlined their 2024 strategies focusing on global expansion, innovative drug development, and digital transformation. Each company emphasized unique approaches, such as maximizing management efficiency, establishing a virtuous cycle, achieving trillion-won revenues, developing improved drugs, and leveraging a two-wing strategy for growth.

Hepatitis B, a significant global health challenge, is expected to see market growth due to increasing prevalence and awareness. Key companies like Gilead Sciences and Brii Biosciences are advancing treatments through clinical trials. The market, driven by antiviral medications, anticipates a surge with new pipeline products. Vaccination remains the most effective prevention method.

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.